Enovis (ENOV) vs Glaukos (GKOS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Glaukos (GKOS) has outperformed Enovis (ENOV) over the past year, gaining 84.1% versus a loss of 45.2%. Over five years, GKOS leads with a +259.9% price change compared with -80.0% for ENOV. Glaukos is the larger company by market cap ($9.77 billion vs $1.02 billion), about 9.6 times the size.
On valuation, Enovis trades at a lower forward P/E (4.9x vs 315.9x for Glaukos).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | GKOS |
|---|---|---|
| Share price | $17.70 | $165.65 |
| Market cap | $1.02B | $9.77B |
| 1-day change | +1.55% | +2.70% |
| YTD return | -34.57% | +42.85% |
| 1-year return | -45.15% | +84.14% |
| 5-year return | -79.99% | +259.86% |
| Forward P/E | 4.93 | 315.92 |
| EPS (TTM) | $-19.23 | $-3.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $507.44M |
| Revenue growth (YoY) | — | +32.33% |
| Net income (latest FY) | — | $-187.69M |
| Gross margin | — | 55.72% |
| Operating margin | — | -39.33% |
| Net margin | — | -36.99% |
| 52-week high | $34.28 | $191.62 |
| 52-week low | $16.70 | $73.16 |
| Distance from 52-week high | -48.37% | -13.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +112.32% | +19.95% |
| Average volume | 1.46M | 831.71K |
| Shares outstanding | 57.67M | 58.98M |
| Employees | 7,802 | 1,094 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Glaukos is about 9.6 times larger than Enovis by market value ($9.77B vs $1.02B).
- GKOS has outperformed ENOV by 129.3 percentage points over the past year.
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
ENOV vs GKOS FAQ
Which is bigger, Enovis or Glaukos?
Glaukos (GKOS) is larger, with a market capitalization of $9.77B compared with $1.02B for Enovis (ENOV).
Which stock has performed better over the past year, ENOV or GKOS?
GKOS returned +84.14% over the past 12 months, compared with -45.15% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Are Enovis and Glaukos in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Enovis and Medical/Dental Instruments for Glaukos.